Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in 2H 2026- CARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology...
Related Questions
What is the potential market size and pricing power for the only oral FGFR3‑selective inhibitor in achondroplasia compared to existing off‑label therapies?
When can we realistically expect safety sentinel cohort data and subsequent regulatory milestones, and how might those timelines impact the stock valuation?
How will the Phase 2 dosing of Dabogratinib affect Tyra's near‑term cash burn and runway?